Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

205.78 -1.54 (-0.74%)

Official Closing Price Updated: 4:10 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

99 100 Next >

Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years

March 21, 2025

From Johnson & Johnson

Via Business Wire

Two Sectors Just Tried And Failed - And That’s Great For Us ↗

March 20, 2025

Technology and healthcare have both tried for a breakout and failed, courtesy of massive economic forces rocking the boat.

Via Talk Markets

Topics Stocks / Equities

Historic Dividend Outperformance ↗

March 20, 2025

One of the most well-known dividend strategies is owning Dividend Aristocrats, of which the NOBL ETF tracks.

Via Talk Markets

Topics ETFs Stocks / Equities

Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough ↗

March 20, 2025

JNJ stock hits Golden Cross, signaling potential long-term upside. Latest breakthrough in lung cancer treatment could provide additional catalyst.

Via Benzinga

Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment ↗

March 10, 2025

Via Benzinga

Honeywell Isn't Going to Let a Little Breakup Ruin Its Growth Plans ↗

March 20, 2025

Via The Motley Fool

Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst ↗

March 18, 2025

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Via Benzinga

FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva ↗

March 18, 2025

Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.

Via Benzinga

Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden ↗

March 18, 2025

Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026.

Via Benzinga

Got $300? Buy These 3 Top Dividend Stocks and Never Look Back. ↗

March 18, 2025

Via The Motley Fool

Resilient Investing: 3 Stocks Built to Weather Market Volatility

March 17, 2025

Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.

Via MarketBeat

Topics Economy

The S&P 500 Is in Correction Territory: 4 Surefire Stocks to Buy Right Now ↗

March 17, 2025

Amazing deals abound within Wall Street's benchmark index.

Via The Motley Fool

Topics Stocks

Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗

March 16, 2025

Large-cap stocks worst performers last week: TER, TTD, COIN, SAIL, GMAB, IBKR, DAL, ADBE, EXPE, HOOD, UAL, AAPL. Are they in your portfolio?

Via Benzinga

Allegations of Inflated Prescription Drug Costs Spark Employee Lawsuit Against JPMorgan ↗

March 15, 2025

A lawsuit has been lodged against JPMorgan Chase by its employees, who claim that the company's prescription drug plan consented to pay exorbitant prices for medications.

Via Benzinga

Topics Lawsuit

Kroger CEO Shake-Up ↗

March 14, 2025

Via The Motley Fool

Cool, Calm, and Collected: 2 Dividend ETFs to Buy During the S&P 500 Sell-Off ↗

March 14, 2025

Via The Motley Fool

Topics ETFs Stocks

Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025 ↗

March 14, 2025

Via The Motley Fool

Topics ETFs Stocks

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

March 14, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

10 Health Care Stocks Whale Activity In Today's Session ↗

March 11, 2025

Via Benzinga

Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You? ↗

March 11, 2025

Vanguard has some excellent dividend ETFs, but they are right for different investors.

Via The Motley Fool

Topics ETFs

Are High-Yield Dividend Stocks Best For Income-Focused Investors? ↗

March 11, 2025

When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But are high-yield stocks always the best route for income-focused investors?...

Via Talk Markets

Topics Stocks / Equities

How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket ↗

March 10, 2025

Via Benzinga

2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger ↗

March 10, 2025

Via The Motley Fool

Why Is Protagonist Therapeutics Stock Trading Higher On Monday? ↗

March 10, 2025

Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints.

Via Benzinga

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out ↗

March 10, 2025

The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment.

Via Investor's Business Daily

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

March 10, 2025

Via Benzinga

3 Dividend Kings Shaking Off Market Woes ↗

March 09, 2025

The market has thrown a tantrum over recent weeks following tariff news and other economic data pointing to a slowing consumer base. While it’s certainly been a turbulent period, several stocks have...

Via Talk Markets

Topics Stocks / Equities World Trade

Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy' ↗

March 07, 2025

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion

Via Benzinga

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug ↗

March 06, 2025

HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.

Via Benzinga

Broaden Your ETF Exposure With These 3 Overlooked Funds

March 06, 2025

These ETFs have outperformed the market so far in 2025 but have lower asset bases than some of the most popular funds among investors.

Via MarketBeat

Topics ETFs Economy Government

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Johnson & Johnson (NY:JNJ)

All News about Johnson & Johnson

Starting at $3.75/week.

Subscribe Today